Jove
Visualize
Contact Us

Related Experiment Videos

Adjuvant therapy for melanoma

V K Sondak1, J A Wolfe

  • 1Taubman Center, Ann Arbor, MI 48109-0331, USA.

Current Opinion in Oncology
|March 1, 1997
PubMed
Summary

High-dose interferon alfa is the first effective adjuvant therapy for melanoma, changing treatment paradigms. This review covers all melanoma adjuvant trials, offering guidance for surgically treated patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Annals of surgical oncology·2020
Same author

Ten-year fracture risk predicted by proximal femur Hounsfield units.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2020
Same author

Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?

Annals of surgical oncology·2020
Same author

Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin.

The British journal of dermatology·2015
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Dermatology
  • Clinical Trials

Background:

  • Adjuvant therapy for melanoma historically lacked proven efficacy.
  • The landscape of melanoma treatment has been significantly impacted by recent advancements.

Purpose of the Study:

  • To review all randomized adjuvant trials in melanoma.
  • To discuss ongoing and upcoming adjuvant studies.
  • To provide recommendations for adjuvant treatment in surgically treated melanoma patients.

Main Methods:

  • Comprehensive literature review of randomized adjuvant trials in melanoma.
  • Analysis of data from completed and ongoing clinical trials.
  • Synthesis of evidence to formulate treatment recommendations.

Main Results:

  • High-dose interferon alfa demonstrated significant activity in a cooperative group trial.
  • This led to Food and Drug Administration approval, establishing a new standard of care.
  • Previous adjuvant therapies showed limited or no benefit.

Conclusions:

  • Adjuvant high-dose interferon alfa is a validated treatment option for melanoma.
  • Further research and ongoing trials are crucial for refining adjuvant strategies.
  • Evidence-based recommendations are provided for clinical practice.

Related Experiment Videos